Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: Alternative biomarkers and therapeutic strategies

Biomarkers in Medicine

Volumn 9, Issue 4, 2015, Pages 363-375

  Caiazza, Francesco ^a,b   Elliott, Louise ^a,b   Fennelly, David ^a,b   Sheahan, Kieran ^a,b   Doherty, Glen A ^a,b   Ryan, Elizabeth J ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

biomarkers; cetuximab; colorectal cancer; EGFR; ErbB; KRAS; monoclonal antibodies; targeted therapy

Indexed keywords

ALPELISIB; B RAF KINASE; BINIMETINIB; CAPMATINIB; CETUXIMAB; DABRAFENIB; DENDRITIC CELL VACCINE; ENCORAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GEDATOLISIB; IRINOTECAN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NERATINIB; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; SONOLISIB; SORAFENIB; TIVANTINIB; UNINDEXED DRUG; VEMURAFENIB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOGENESIS; DRUG DOSE ESCALATION; DRUG EFFICACY; EFFECTOR CELL; GENE; HER2 GENE; HUMAN; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84964308944     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.5     Document Type: Review

References (98)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40. countries in 2012. Eur. J. Cancer 49(6), 1374-1403 (2013).
2. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17(6), 1471-1474 (2010).
3. Hagan S, Orr MCM, Doyle B. Targeted therapies in colorectal cancer -an integrative view by PPPM. EPMA J. 4(1), 3 (2013).
4. National Cancer Intelligence Network. www.ncin.org.uk
5. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28(7), 1254-1261 (2010).
6. Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist 15(1), 73-84 (2010).
7. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Crit. Rev. Oncol. Hematol. 85(1), 45-81 (2013).
8. Lièvre A, Bachet J-B, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
9. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
10. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366(1), 2-16 (2006).
11. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11(11), 761-774 (2011).
12. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26(3), 374-379 (2008).
13. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67(6), 2643-2648 (2007).
14. Bokemeyer C, Cutsem EV, Rougier P et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 48(10), 1466-1475 (2012).
15. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
16. Peeters M, Price TJ, Cervantes A et al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706-4713 (2010).
17. Douillard J-Y, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28(31), 4697-4705 (2010).
18. Practice EOGAI, Group PEW. Recommendations from the EGAPP working group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genet. Med. 15(7), 517-527 (2013).
19. Kumar SS, Price TJ, Mohyieldin O, Borg M, Townsend A, Hardingham JE. KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model. Gastrointest. Cancer Res. 7(1), 23-26 (2014).
20. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16), 1812-1820 (2010).
21. Yoon HH, Tougeron D, Shi Q et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance). Clin. Cancer Res. 20(11), 3033-3043 (2014).
22. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 101(4), 715-721 (2009).
23. Douillard J-Y, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369(11), 1023-1034 (2013).
24. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11(8), 753-762 (2010).
25. Ciardiello F, Lenz H-J, Köhne C-H et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab J. Clin. Oncol. 32(Suppl. 15), Abstract 3506 (2014).
26. Peeters M, Oliner KS, Parker A et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized Phase III study of metastatic colorectal cancer. Clin. Cancer Res. 19(7), 1902-1912 (2013).
27. Schirripa M, Cremolini C, Loupakis F et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int. J. Cancer 136(1), 83-90 (2014).
28. Sclafani F, Gullo G, Sheahan K, Crown J. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. Crit. Rev. Oncol. Hematol. 87(1), 55-68 (2013).
29. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705-5712 (2008).
30. Mao C, Liao R-Y, Qiu L-X, Wang X-W, Ding H, Chen Q. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol. Biol. Rep. 38(4), 2219-2223 (2011).
31. Tsuda M, Okamoto K, Muguruma N et al. Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model. J. Gastroenterol. Hepatol. 28(10), 1616-1623 (2013).
32. Thompson H. US National Cancer Institute's new RAS project targets an old foe. Nat. Med. 19(8), 949-950 (2013).
33. Yang H, Higgins B, Kolinsky K et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 72(3), 779-789 (2012).
34. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387), 100-103 (2012).
35. Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol. Ther. 14(8), 703-710 (2013).
36. Troiani T, Napolitano S, Vitagliano D et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin. Cancer Res. 20(14), 3775-3786 (2014).
37. Hochster HS, Uboha N, Messersmith W et al. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother. Pharmacol. 75(1), 17-23 (2014).
38. Lamba S, Russo M, Sun C et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 8(5), 1475-1483 (2014).
39. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009).
40. Sartore-Bianchi A, Martini M, Molinari F et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69(5), 1851-1857 (2009).
41. Prenen H, De Schutter J, Jacobs B et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res. 15(9), 3184-3188 (2009).
42. Huang L, Liu Z, Deng D et al. Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch. Med. Sci. 10(1), 1-9 (2014).
43. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105(7), 2652-2657 (2008).
44. Lin JS, Webber EM, Senger CA, Holmes RS, Whitlock EP. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. Am. J. Cancer Res. 1(5), 650-662 (2011).
45. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407), 330-337 (2012).
46. Garrido-Laguna I, Hong DS, Janku F et al. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS ONE 7(5), e38033 (2012).
47. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 4(10), e7287 (2009).
48. Yang Z-Y, Wu X-Y, Huang Y-F et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int. J. Cancer 133(8), 1914-1925 (2013).
49. Tian S, Simon I, Moreno V et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62(4), 540-549 (2013).
50. Misale S, Yaeger R, Hobor S et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404), 532-536 (2012).
51. Diaz LA, Williams RT, Wu J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404), 537-540 (2012).
52. Martinelli E, Troiani T, D'Aiuto E et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int. J. Cancer 133(9), 2089-2101 (2013).
53. Klinger B, Sieber A, Fritsche-Guenther R et al. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol. Syst. Biol. 9, 673 (2013).
54. Dunn EF, Iida M, Myers RA et al. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene 30(5), 561-574 (2011).
55. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159-3167 (2000).
56. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1(6), 508-523 (2011).
57. Martin V, Landi L, Molinari F et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br. J. Cancer 108(3), 668-675 (2013).
58. Rubinson DA, Hochster HS, Ryan DP et al. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a Phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Invest. New Drugs 32(1), 113-122 (2013).
59. Lédel F, Hallström M, Ragnhammar P, Öhrling K, Edler D. HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. Eur. J. Cancer 50(3), 656-662 (2014).
60. Beji A, Horst D, Engel J, Kirchner T, Ullrich A. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin. Cancer Res. 18(4), 956-968 (2012).
61. Sun C, Hobor S, Bertotti A et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7(1), 86-93 (2014).
62. Bardelli A, Corso S, Bertotti A et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3(6), 658-673 (2013).
63. Luraghi P, Reato G, Cipriano E et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res. 74(6), 1857-1869 (2014).
64. Van Schaeybroeck S, Kalimutho M, Dunne PD et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 7(6), 1940-1955 (2014).
65. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230-3237 (2007).
66. Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a Phase I dose-escalation study. J. Clin. Oncol. 28(7), 1181-1189 (2010).
67. Pentheroudakis G, Kotoula V, De Roock W et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13, 49 (2013).
68. Jonker DJ, Karapetis CS, Harbison C et al. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br. J. Cancer 110(3), 648-655 (2013).
69. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 8(12), 932-941 (2008).
70. Merchant NB, Voskresensky I, Rogers CM et al. TACE/ ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin. Cancer Res. 14(4), 1182-1191 (2008).
71. Van Schaeybroeck S, Kyula JN, Fenton A et al. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res. 71(3), 1071-1080 (2011).
72. Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG. Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res. 16(13), 3378-3389 (2010).
73. McGowan PM, Mullooly M, Caiazza F et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann. Oncol. 24(2), 362-369 (2013).
74. Richards FM, Tape CJ, Jodrell DI, Murphy G. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS ONE 7(7), e40597 (2012).
75. Sisto M, Lisi S, D'Amore M, Lofrumento DD. The metalloproteinase ADAM17 and the epidermal growth factor receptor (EGFR) signaling drive the inflammatory epithelial response in Sjögren's syndrome. Clin. Exp. Med. (2014).
76. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 32(8), 380-387 (2011).
77. Patel D, Guo X, Ng S et al. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum. Antibodies 19(4), 89-99 (2010).
78. Kubach J, Hubo M, Amendt C, Stroh C, Jonuleit H. IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity. Int. J. Cancer 136(4), 821-830 (2014).
79. Calemma R, Ottaiano A, Trotta AM et al. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. J. Transl. Med. 10, 232 (2012).
80. Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc. Natl Acad. Sci. USA 109(51), 21046-21051 (2012).
81. Kohrt HE, Colevas AD, Houot R et al. Targeting CD137 enhances the efficacy of cetuximab. J. Clin. Invest. 124(6), 2668-2682 (2014).
82. Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. Oncoimmunology 2(6), e24677 (2013).
83. Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target. Oncol. 8(3), 173-181 (2013).
84. Xynos ID, Karadima ML, Voutsas IF et al. Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer. Oncology. 84(5), 273-283 (2013).
85. Akbay EA, Koyama S, Carretero J et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3(12), 1355-1363 (2013).
86. Di Leva G, Garofalo M, Croce CM. MicroRNAs in Cancer. Annu. Rev. Pathol. Mech. Dis. 9(1), 287-314 (2014).
87. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA. MicroRNAs, ultraconserved genes and colorectal cancers. Int. J. Biochem. Cell Biol. 42(8), 1291-1297 (2010).
88. Mlcochova J, Faltejskova P, Nemecek R, Svoboda M, Slaby O. MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J. Cancer Res. Clin. Oncol. 139(10), 1615-1624 (2013).
89. Pagliuca A, Valvo C, Fabrizi E et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 32(40), 4806-4813 (2013).
90. Pichler M, Winter E, Stotz M et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br. J. Cancer 106(11), 1826-1832 (2012).
91. Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene 32(20), 2576-2585 (2013).
92. Chivukula RR, Shi G, Acharya A et al. An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell 157(5), 1104-1116 (2014).
93. Schou JV, Rossi S, Jensen BV et al. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PLoS ONE 9(6), e99886 (2014).
94. Manceau G, Imbeaud S, Thiébaut R et al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 20(12), 3338-3347 (2014).
95. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15(8), 541-555 (2014).
96. Malapelle U, Vigliar E, Sgariglia R et al. Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. J. Clin. Pathol. 68(1), 64-68 (2015).
97. Esplin ED, Snyder MP. Genomic era diagnosis and management of hereditary and sporadic colon cancer. World J. Clin. Oncol. 5(5), 1036-1047 (2014).
98. FOCUS4. www.focus4trial.org